Base editing and prime editing are precision genome editing methods that rewrite DNA without the double-strand break standard CRISPR cutting relies on. Base editing, first described in Nature in 2016, converts one DNA base into another; prime editing, described in Nature in 2019, writes new sequence into a target site, per the two papers.
Why did editors move away from double-strand breaks?
Standard CRISPR-Cas9 editing cuts both DNA strands and lets the cell repair the break — a powerful tool with a messy repair profile. As the 2016 Nature base editing paper put it, current genome-editing technologies "introduce double-stranded (ds) DNA breaks at a target locus as the first step to gene correction," and because most genetic diseases arise from point mutations, approaches that cut to correct a single nucleotide "are inefficient and typically induce an abundance of random insertions and deletions (indels) at the target locus resulting from the cellular response to dsDNA breaks."
The clinical translation of editing is already real: FDA approved the first CRISPR/Cas9-based therapy, Vertex's Casgevy, in December 2023, per the agency's announcement. That therapy edits blood stem cells outside the body. But for many point mutations, cut-and-repair editing is the wrong instrument, and the indel byproducts are exactly the risk a therapeutic program wants to minimize.
Both newer methods therefore keep the targeting machinery of CRISPR while removing the cut. The consequence is a different trade-off space: fewer indels and less dependence on the cell's repair pathways, in exchange for more complex editor proteins and a constrained menu of possible edits. That menu is what defines which diseases each platform can realistically address.
What can base editing actually change?
Base editing directly converts one base into another without cleaving the DNA backbone. The original paper reports "the development of 'base editing', a new approach to genome editing that enables the direct, irreversible conversion of one target DNA base into another in a programmable manner, without requiring dsDNA backbone cleavage or a donor template," using engineered fusions of CRISPR/Cas9 and a cytidine deaminase that mediate "the direct conversion of cytidine to uridine, thereby effecting a C→T (or G→A) substitution."
Efficiency and precision were quantified in the same paper. The resulting base editors convert cytidines "within a window of approximately five nucleotides," and in four transformed human and murine cell lines, second- and third-generation editors achieved "permanent correction of ~15–75% of total cellular DNA with minimal (typically ≤1%) indel formation." The authors' summary judgment: "Base editing expands the scope and efficiency of genome editing of point mutations."
The constraint is the chemistry. A cytosine base editor accesses C-to-T changes; an adenine base editor, developed later by the same field, accesses A-to-G. Within the editing window, any convertible base can be changed — wanted or not — so bystander edits are a design problem. Base editing cannot insert, delete, or swap bases for a different letter pair; it is a point-mutation instrument.
What does prime editing add?
Prime editing, described in the 2019 Nature paper "Search-and-replace genome editing without double-strand breaks or donor DNA," extends the repertoire. The method "directly writes new genetic information into a specified DNA site using a catalytically impaired Cas9 endonuclease fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit," per the paper's abstract.
The scope claim is broad: the authors report performing "more than 175 edits in human cells, including targeted insertions, deletions, and all 12 types of point mutation without the need for double-strand breaks or donor DNA." The prime editing paper positions the method as a search-and-replace system: find the site with the guide, replace the sequence with the encoded edit.
In practice, prime editing trades some efficiency for generality. Early implementations showed lower editing efficiencies than optimized base editors in many loci, and the editor is a larger, more complex payload for delivery — a real constraint for in vivo programs where vector cargo capacity limits what can be packaged. Base editors remain the tool of choice where the needed change is a compatible single-base conversion; prime editing is the tool when the needed change is anything else.
How do the two methods compare side by side?
| Feature | Base editing | Prime editing |
|---|---|---|
| Edit types | C→T (G→A) and A→G (T→C) conversions | All 12 base-to-base conversions plus small insertions and deletions |
| DNA backbone cut | None (nicking at most) | Single-strand nick only |
| Donor DNA required | No | No |
| Key enzyme | Cas9-deaminase fusion | Nickase Cas9 fused to reverse transcriptase |
| Reported indel byproducts | Typically ≤1% in the 2016 cell-line data | Low, per the 2019 paper, without a universal figure |
The gap between these methods and the clinic should be stated plainly. Casgevy's approval shows ex vivo editing can become medicine; base-edited and prime-edited candidates have entered clinical testing, but approved therapies built on these specific editors remain a smaller set, and in vivo delivery, tissue targeting, and long-term safety data are still being generated. The papers describe what the enzymes do in cells; the clinic decides what they mean for patients.
What stands between these editors and approved medicines?
Delivery is the first constraint. Editor proteins are large: a prime editor is a fusion of a nickase Cas9 and a reverse transcriptase, and packaging that payload into a viral vector tests cargo limits that a standard Cas9 does not. Lipid nanoparticles and engineered vectors have carried editors into the liver in clinical programs, but delivery to muscle, brain, and other solid tissues at therapeutic doses remains an unsolved engineering problem. Ex vivo editing — editing patient cells in a lab and returning them — sidesteps delivery but adds manufacturing complexity and conditioning regimens.
Specificity is the second. Removing the double-strand break removes indel byproducts, but off-target base conversions and RNA off-targets from the deaminase component are separate questions, each requiring its own assay strategy. Developers publish off-target analyses at candidate loci, and regulators expect the specificity file to be locus-specific rather than generic to the platform.
durability question — whether an edit made once persists for a patient's lifetime in the edited cell lineage — is answered by follow-up data, not by mechanism. The honest summary is that base editing and prime editing are proven editors in cells and increasingly in trials, while the number of approved therapies built on them is still being written.
What was measured, and in what system?
A reader should hold the evidence claims at their actual resolution. The base editing paper's headline numbers — correction of roughly 15-75% of total cellular DNA with minimal indel formation — were measured in four transformed human and murine cell lines, not in patients. The prime editing paper's 175-plus edits were performed in human cells in culture. Both results established what the enzymes can do to DNA in a dish under controlled conditions.
What they did not establish is clinical benefit in any disease, and the gap is the standard one in translational genetics: delivery to the right tissue at the right dose, durability of the edit in a living lineage, immune response to bacterial editor proteins, and long-term safety in the target population. The Casgevy approval shows the ex vivo route across that gap is passable. The in vivo route for these editors is being walked now, one trial at a time, and each program reports its own numbers with its own endpoints.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
